Literature DB >> 22173986

Age, CAG repeat length, and clinical progression in Huntington's disease.

Adam Rosenblatt1, Brahma V Kumar, Alisa Mo, Claire S Welsh, Russell L Margolis, Christopher A Ross.   

Abstract

The objective of this study was to further explore the effect of CAG repeat length on the rate of clinical progression in patients with Huntington's disease. The dataset included records for 569 subjects followed prospectively at the Baltimore Huntington's Disease Center. Participants were seen for a mean of 7.1 visits, with a mean follow-up of 8.2 years. Subjects were evaluated using the Quantified Neurologic Examination and its Motor Impairment subscale, the Mini-Mental State Examination, and the Huntington's disease Activities of Daily Living Scale. By itself, CAG repeat length showed a statistically significant but small effect on the progression of all clinical measures. Contrary to our previous expectations, controlling for age of onset increased the correlation between CAG repeat length and progression of all variables by 69% to 159%. Graphical models further supported the idea that individuals with smaller triplet expansions experience a more gradual decline. CAG repeat length becomes an important determinant of clinical prognosis when accounting for age of onset. This suggests that the aging process itself influences clinical outcomes in Huntington's disease. Inconsistent results in prior studies examining CAG repeat length and progression may indeed reflect a lack of age adjustment.
Copyright © 2011 Movement Disorder Society.

Entities:  

Mesh:

Year:  2011        PMID: 22173986     DOI: 10.1002/mds.24024

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  33 in total

Review 1.  Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics.

Authors:  Tiago A Mestre; Cristina Sampaio
Journal:  Curr Neurol Neurosci Rep       Date:  2017-02       Impact factor: 5.081

2.  [Choreatic syndrome at 79 years old: late manifestation of Huntington's chorea].

Authors:  I Vachalova; V Golden; J Großkopf; J G Heckmann
Journal:  Nervenarzt       Date:  2013-12       Impact factor: 1.214

3.  Tracking motor impairments in the progression of Huntington's disease.

Authors:  Jeffery D Long; Jane S Paulsen; Karen Marder; Ying Zhang; Ji-In Kim; James A Mills
Journal:  Mov Disord       Date:  2013-10-21       Impact factor: 10.338

4.  Sleep in Huntington's disease: a systematic review and meta-analysis of polysomongraphic findings.

Authors:  Ye Zhang; Rong Ren; Linghui Yang; Junying Zhou; Yun Li; Jie Shi; Lin Lu; Larry D Sanford; Xiangdong Tang
Journal:  Sleep       Date:  2019-10-09       Impact factor: 5.849

5.  Comparison of mid-age-onset and late-onset Huntington's disease in Finnish patients.

Authors:  Jussi O T Sipilä; Tommi Kauko; Markku Päivärinta; Kari Majamaa
Journal:  J Neurol       Date:  2017-08-28       Impact factor: 4.849

Review 6.  Diminishing return for mechanistic therapeutics with neurodegenerative disease duration?: There may be a point in the course of a neurodegenerative condition where therapeutics targeting disease-causing mechanisms are futile.

Authors:  David C Rubinsztein; Harry T Orr
Journal:  Bioessays       Date:  2016-08-01       Impact factor: 4.345

Review 7.  Huntington disease: natural history, biomarkers and prospects for therapeutics.

Authors:  Christopher A Ross; Elizabeth H Aylward; Edward J Wild; Douglas R Langbehn; Jeffrey D Long; John H Warner; Rachael I Scahill; Blair R Leavitt; Julie C Stout; Jane S Paulsen; Ralf Reilmann; Paul G Unschuld; Alice Wexler; Russell L Margolis; Sarah J Tabrizi
Journal:  Nat Rev Neurol       Date:  2014-03-11       Impact factor: 42.937

8.  The folding equilibrium of huntingtin exon 1 monomer depends on its polyglutamine tract.

Authors:  Jose M Bravo-Arredondo; Natalie C Kegulian; Thomas Schmidt; Nitin K Pandey; Alan J Situ; Tobias S Ulmer; Ralf Langen
Journal:  J Biol Chem       Date:  2018-10-12       Impact factor: 5.157

9.  Altered brain iron content and deposition rate in Huntington's disease as indicated by quantitative susceptibility MRI.

Authors:  Lin Chen; Jun Hua; Christopher A Ross; Shuhui Cai; Peter C M van Zijl; Xu Li
Journal:  J Neurosci Res       Date:  2018-11-29       Impact factor: 4.164

Review 10.  Potassium channel dysfunction in neurons and astrocytes in Huntington's disease.

Authors:  Xiao Zhang; Jie-Qing Wan; Xiao-Ping Tong
Journal:  CNS Neurosci Ther       Date:  2018-01-27       Impact factor: 5.243

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.